Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma

被引:29
作者
Robak, T [1 ]
Gora-Tybor, J [1 ]
Urbanska-Rys, H [1 ]
Krykowski, E [1 ]
机构
[1] Med Univ Lodz, Dept Hematol, PL-93513 Lodz, Poland
关键词
2-chlorodeoxyadenosine; mitoxantrone; dexamethasone; non-Hodgkin's lymphoma;
D O I
10.3109/10428199909167397
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of our phase II study was to determine the effectiveness of combined chemotherapy consisting of 2-hour intravenous infusion of 2-CdA, mitoxantrone and dexamethasone (CMD) regimen in the treatment of heavily previously treated patients with refractory or relapsed low grade non-Hodgkin's lymphoma (LGNHL). All of the 14 patients had clinical stage IV disease, mast of them had B symptoms and elevated LDH levels. All cases were refractory to standard chemotherapy or had recurrent relapses having received at least 5 courses of prior chemotherapy. All patients received at least one cycle of CMD (range, 1-4). A total of 35 courses of CMD were given to the entire group. Complete response (CR) was obtained only in one patient (7.1 %) and partial response (PR) in 3 (21.4%) with an overall response rate of 28.5%. The major toxicity was myelosuppression and 35% of the patients had infection. One patient died of sepsis. These results suggest that the addition of other drugs to 2-CdA in heavily treated patients with refractory or relapsing disease may not be more advantageous when composed to giving 2-CdA alone.
引用
收藏
页码:359 / 363
页数:5
相关论文
共 50 条
[41]   Hypercalcemia: First sign of medullar transformation of low grade non-Hodgkin's lymphoma. [J].
Joly, F ;
Reman, O ;
Penther, D ;
Levaltier, X ;
Troussard, X ;
Leporrier, M .
BULLETIN DU CANCER, 1996, 83 (02) :154-156
[42]   Non-Platinum Containing Regimen of Gemcitabine, Vinorelbine and Dexamethasone as Salvage Therapy in Relapsed/Refractory Hodgkin's Lymphoma [J].
Ganesan, Prasanth ;
Mehra, Nikita ;
Joel, Anjana ;
Radhakrishnan, Venkatraman ;
Dhanushkodi, Manikandan ;
Jayachandran, P. K. ;
Shankar, Krupa ;
Ganesan, Trivadi S. ;
Sagar, Tenali .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 :S230-S230
[43]   Fludarabine-induced tumour lysis in low-grade non-Hodgkin's lymphoma [J].
Killick, S ;
Mercieca, J ;
Nandi, A ;
Behrens, J .
CLINICAL AND LABORATORY HAEMATOLOGY, 1997, 19 (01) :79-80
[44]   Urinary albumin excretion is a predictor of response to treatment and disease progression in low-grade non-Hodgkin's lymphoma [J].
Pedersen, LM ;
Sorensen, PG .
LEUKEMIA & LYMPHOMA, 2004, 45 (03) :547-551
[45]   Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin's Lymphoma in Iran [J].
Hatam, Nahid ;
Dehghani, Mehdi ;
Habibian, Mostafa ;
Jafari, Abdosaleh .
IRANIAN JOURNAL OF CANCER PREVENTION, 2015, 8 (05)
[46]   A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group [J].
A. Wrzesień-Kuś ;
T. Robak ;
A. Wierzbowska ;
E. Lech-Marańda ;
A. Pluta ;
E. Wawrzyniak ;
A. Krawczyńska ;
K. Kuliczkowski ;
G. Mazur ;
M. Kiebiński ;
A. Dmoszyńska ;
M. Wach ;
A. Hellmann ;
W. Baran ;
J. Hołowiecki ;
S. Kyrcz-Krzemień ;
S. Grosicki .
Annals of Hematology, 2005, 84 :557-564
[47]   A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group [J].
Wrzesien-Kus, A ;
Robak, T ;
Wierzbowska, A ;
Lech-Maranda, E ;
Pluta, A ;
Wawrzyniak, E ;
Krawczynska, A ;
Kuliczkowski, K ;
Mazur, G ;
Kiebinski, M ;
Dmoszynska, A ;
Wach, M ;
Hellmann, A ;
Baran, W ;
Holowiecki, J ;
Kyrcz-Krzemien, S ;
Grosicki, S .
ANNALS OF HEMATOLOGY, 2005, 84 (09) :557-564
[48]   Preliminary results on the activity of oxaliplatin (L-OHP) in refractory recurrent non-Hodgkin's lymphoma patients [J].
Germann, N ;
Brienza, S ;
Rotarski, M ;
Emile, JF ;
Di Palma, M ;
Musset, M ;
Reynes, M ;
Soulié, P ;
Cvitkovic, E ;
Misset, JL .
ANNALS OF ONCOLOGY, 1999, 10 (03) :351-354
[49]   High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy [J].
Proctor, SJ ;
Taylor, PRA ;
Angus, B ;
Wood, K ;
Lennard, AL ;
Lucraft, H ;
Carey, PJ ;
Stark, A ;
Iqbal, A ;
Haynes, A ;
Russel, N ;
Leonard, RCF ;
Culligan, D ;
Conn, J ;
Jackson, GH .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 66 :28-32
[50]   Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma [J].
Misgeld, E ;
Germing, U ;
Aul, C ;
Gattermann, N .
LEUKEMIA RESEARCH, 2001, 25 (01) :95-98